Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome
CM Legendre, C Licht, P Muus… - … England Journal of …, 2013 - Mass Medical Soc
Background Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
[HTML][HTML] Overview of complement activation and regulation
Complement is an important component of the innate immune system that is crucial for
defense from microbial infections and for clearance of immune complexes and injured cells …
defense from microbial infections and for clearance of immune complexes and injured cells …
Complement: a key system for immune surveillance and homeostasis
Nearly a century after the significance of the human complement system was recognized, we
have come to realize that its functions extend far beyond the elimination of microbes …
have come to realize that its functions extend far beyond the elimination of microbes …
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults
V Fremeaux-Bacchi, F Fakhouri, A Garnier… - Clinical Journal of the …, 2013 - journals.lww.com
Results Onset of aHUS occurred as frequently during adulthood (58.4%) as during
childhood (41.6%). The percentages of patients who developed the disease were 23 …
childhood (41.6%). The percentages of patients who developed the disease were 23 …
Complement activation, regulation, and molecular basis for complement‐related diseases
The complement system is an essential element of the innate immune response that
becomes activated upon recognition of molecular patterns associated with microorganisms …
becomes activated upon recognition of molecular patterns associated with microorganisms …
[HTML][HTML] Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group
Pregnancy and postpartum are high-risk periods for different forms of thrombotic
microangiopathy (TMA). However, the management of pregnancy-associated TMA remains …
microangiopathy (TMA). However, the management of pregnancy-associated TMA remains …
HUS and atypical HUS
TS Jokiranta - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …
Thrombotic thrombocytopenic purpura
BS Joly, P Coppo, A Veyradier - Blood, The Journal of the …, 2017 - ashpublications.org
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic
microangiopathy characterized by microangiopathic hemolytic anemia, severe …
microangiopathy characterized by microangiopathic hemolytic anemia, severe …
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice
N Knoers, C Antignac, C Bergmann… - Nephrology Dialysis …, 2022 - academic.oup.com
The overall diagnostic yield of massively parallel sequencing–based tests in patients with
chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These …
chronic kidney disease (CKD) is 30% for paediatric cases and 6–30% for adult cases. These …